Our efforts were further prompted by our observation that B7-H3 is overexpressed in bone and soft tissue sarcomas independently of subtype, as tumor associated antigens with homogenous overexpression are a prerequisite for success of immunotherapeutic treatment. The gene discussed is CD276; the disease is neoplasm.